- Goal is to raise $4 million to help company finance its planned projects
- Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
- ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases
Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://nnw.fm/If7xI). The funds would be used to finance its planned projects in the new year and for general working capital (http://nnw.fm/AvqM6), with share cancellation by company founders counteracting dilution.
ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://nnw.fm/cYPK2). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.
Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”
The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.
ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.
ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.
For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
No comments:
Post a Comment